TEE
AERI

Tibra Equities Europe’s Aerie Pharmaceuticals AERI Stock Holding History

Tibra Equities Europe’s Portfolio AERI Stock Details AERI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-19,400
Closed -$922K – 478
2019
Q1 		$922K Buy
+19,400
New +$854K 0.09% 179

Other funds holding AERI

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Tibra Equities Europe's AERI Position: Q2 2019 in Review

Tibra Equities Europe sold out of Aerie Pharmaceuticals (AERI) in Q2 2019, closing a stake of 19,400 shares — an estimated $922K sold.

Tibra Equities Europe first reported a position in AERI in Q1 2019 and held it in 1 quarter. The position peaked at $922K in Q1 2019. 167 funds tracked by Wall St. Rank hold AERI as of Q2 2019.

  • Tibra Equities Europe reported no remaining Aerie Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
  • Tibra Equities Europe sold 19,400 Aerie Pharmaceuticals shares in Q2 2019, an estimated $922K.
  • Tibra Equities Europe first reported a position in Aerie Pharmaceuticals in Q1 2019 and held it in 1 quarter.
  • Tibra Equities Europe's Aerie Pharmaceuticals position peaked at $922K in Q1 2019.
  • 167 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q2 2019.

Based on Tibra Equities Europe's 13F filing for Q2 2019, filed 1 Aug 2019.